胃肠癌新辅助化.pptVIP

胃癌新辅助化疗/围手术期化疗局部进展期胃癌治疗新模式! 可切除胃癌围手术期化疗---MAGIC trial 胃癌（占85%） 或低位食管癌（15%） ECF* 3cs-手术-ECF 3cs 单一手术 N=250 5Y 38% N=253 5Y 23% ECF: E 50mg/m2 C 60mg/m2 FU 200mg/m2/d civ D.Cuuningham 2005 ASCO abs 4001 Cunningham et al, NEJM 2006 Patients at risk Logrank p-value = 0.009 Hazard Ratio = 0.75 (95% CI 0.60 - 0.93) CSC S 250 168 111 79 52 38 27 253 155 80 50 31 18 9 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Months from randomization 0 12 24 36 48 60 72 149 250 170 253 Events Total CSC S Survival rate Overall Survival Patients at risk Logrank p-value = 0.009 Hazard Ratio = 0.75 (95% CI 0.6